The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) Study

被引:50
|
作者
Durovni, Betina [2 ,3 ]
Cavalcante, Solange C. [2 ,4 ]
Saraceni, Valeria [2 ]
Vellozo, Vitoria [2 ]
Israel, Giselle [2 ]
King, Bonnie S. [5 ]
Cohn, Silvia [1 ]
Efron, Anne [5 ]
Pacheco, Antonio G. [4 ]
Moulton, Lawrence H. [5 ]
Chaisson, Richard E. [1 ,5 ,6 ]
Golub, Jonathan E. [1 ,6 ]
机构
[1] Johns Hopkins Univ, Sch Med, Ctr TB Res, Baltimore, MD 21231 USA
[2] Municipal Hlth Secretariat, Rio De Janeiro, Brazil
[3] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil
[4] Fiocruz MS, BR-21045900 Rio De Janeiro, Brazil
[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
[6] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
adherence; HIV; implementation; isoniazid preventive therapy; tuberculosis; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED PATIENTS; DE-JANEIRO; TUBERCULOSIS; BRAZIL; TRIAL; RISK; IMPACT;
D O I
10.1097/01.aids.0000391022.95412.a6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The TB/HIV in Rio (THRio) study was launched in September 2005 to assess the impact of integrated tuberculosis (TB) and HIV treatment strategies in 29 HIV clinics in Rio de Janeiro, Brazil. Design: THRio is a cluster-randomized trial (CRT) to determine whether routine screening for and treatment of latent TB in HIV clinic patients with access to anti-retroviral therapy will reduce TB incidence at the clinic level. THRio is part of the Consortium to Respond Effectively to AIDS/TB Epidemic that is implementing research studies to assess the impact of bold, new public health paradigms for controlling the AIDS/TB epidemic. Methods: Twenty-nine public primary HIV clinics were randomly assigned a date to begin implementing TB screening procedures and provision of isoniazid preventive therapy (IPT) for TB/HIVcoinfected patients. Final analysis of the CRT is expected in 2011. Results: Starting at date of tuberculin skin test (TST)/IPT implementation at each clinic through August 2010, 1670 HIV-infected patients initiated IPT, of which 215 are still receiving treatment. Of the remaining 1455 patients, 1230 (85%) completed therapy and only 20 (1.2%) patients initiating IPT reported adverse reactions leading to discontinuation of therapy. IPT completion was higher among HIV-infected patients receiving HAART (87%) than those not yet receiving HAART (79%, P < 0.01). Times to TST and IPT have markedly decreased postintervention, but remain considerably long. The richness of the THRio database has resulted in several analyses of this expansive cohort of HIV-infected patients that are reviewed here. Conclusions: The national implementation of TST and IPT for HIV-positive patients in Brazil has been invigorated partly due to THRio's baseline results. Expanded use of IPT in HIV patients in Rio de Janeiro is achievable with high adherence and low adverse events, although this effort requires a package of activities including training, advocacy and reorganization of services. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:S49 / S56
页数:8
相关论文
共 50 条
  • [1] Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study
    Lester, Rebecca
    Hamilton, Robin
    Charalambous, Salome
    Dwadwa, Thobeka
    Chandler, Clare
    Churchyard, Gavin J.
    Grant, Alison D.
    [J]. AIDS, 2010, 24 : S45 - S48
  • [2] Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study
    Azadi, M.
    Bishai, D. M.
    Dowdy, D. W.
    Moulton, L. H.
    Cavalcante, S.
    Saraceni, V.
    Pacheco, A. G.
    Cohn, S.
    Chaisson, R. E.
    Durovni, B.
    Golub, J. E.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2014, 18 (12) : 1443 - 1448
  • [3] Long-term Protection From Isoniazid Preventive Therapy for Tuberculosis in HIV-Infected Patients in a Medium-Burden Tuberculosis Setting: The TB/HIV in Rio (THRio) Study
    Golub, Jonathan E.
    Cohn, Silvia
    Saraceni, Valeria
    Cavalcante, Solange C.
    Pacheco, Antonio G.
    Moulton, Lawrence H.
    Durovni, Betina
    Chaisson, Richard E.
    [J]. CLINICAL INFECTIOUS DISEASES, 2015, 60 (04) : 639 - 645
  • [4] Prevalent Tuberculosis at HIV Diagnosis in Rio de Janeiro, Brazil: The TB/HIV in Rio (THRio) Cohort
    Saraceni, Valeria
    Cohn, Silvia
    Cavalcante, Solange C.
    Pacheco, Antonio G. F.
    Moulton, Lawrence H.
    Chaisson, Richard E.
    Durovni, Betina
    Golub, Jonathan E.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 67 (01) : 98 - 101
  • [5] HIV, Pregnancy, and Isoniazid Preventive Therapy
    Tiendrebeogo, Thierry
    Anglaret, Xavier
    Becquet, Renaud
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1184 - 1184
  • [6] Isoniazid preventive therapy in HIV infection
    Dodd, Lori Elizabeth
    Wilkinson, Robert John
    [J]. LANCET, 2011, 377 (9777): : 1548 - 1550
  • [7] Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania
    Olivia F. Hunter
    Furaha Kyesi
    Amrit Kaur Ahluwalia
    Zeinabou Niamé Daffé
    Patricia Munseri
    C. Fordham von Reyn
    Lisa V. Adams
    [J]. BMC Infectious Diseases, 20
  • [8] Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania
    Hunter, Olivia F.
    Kyesi, Furaha
    Ahluwalia, Amrit Kaur
    Daffe, Zeinabou Niame
    Munseri, Patricia
    von Reyn, C. F.
    Adams, Lisa, V
    [J]. BMC INFECTIOUS DISEASES, 2020, 20 (01)
  • [9] Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons
    Mary Kagujje
    Muhau L. Mubiana
    Eugenia Mwamba
    Monde Muyoyeta
    [J]. BMC Public Health, 19
  • [10] Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons
    Kagujje, Mary
    Mubiana, Muhau L.
    Mwamba, Eugenia
    Muyoyeta, Monde
    [J]. BMC PUBLIC HEALTH, 2019, 19 (01)